Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
For patients hospitalized with acute decompensated heart failure,volume removal remains the
primary therapeutic objective. The current standard of care remains loop diuretics.The high
likelihood of readmissions and poor outcomes highlights the need to examine and improve
in-hospital protocols for these patients. Ultrafiltration allows for greater volume removal,
less neurohormonal stimulation and greater sodium removal.However it is associated with
increased costs, line complications, and relative immobility during treatment. Tolvaptan in
addition to diuretic therapy has been shown to improve the amount of volume removed compared
to diuretic alone.
The study proposes to compare the strategy of adding tolvaptan to usual care with
ultrafiltration as primary mode of therapy in acute decompensated HF(ADHF) patients.
Hypothesis: addition of tolvaptan to usual care for hospitalized HF patients will result in:
- greater volume and weight reduction compared with usual care
- similar efficacy outcomes compared with ultrafiltration, with less complications of
therapy